Vertex Revenue Soars on Growth for Cystic Fibrosis Drugs

Vertex Pharmaceuticals said third-quarter revenue soared 73% as the Boston biotechnology company posted better-than-expected sales of cystic fibrosis drugs Kalydeco and recently launched Orkambi.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news